Compound News and Research

RSS

H. pylori infection could play a role in Parkinson's disease development

The stomach bacteria responsible for ulcers could also play a role in the development of Parkinson's disease according to research presented today at the 111th General Meeting of the American Society for Microbiology.

23 May 2011

New insights into bone diseases

A study by researchers at Children's Hospital Boston and collaborators at other institutions has provided new insights into the means by which bone cells produce new bone in response to mechanical stresses, such as exercise.

23 May 2011

Stony Brook University CFB establishes Biotechnology Commercialization Fund

The Center for Biotechnology (CFB) at Stony Brook University has established the Biotechnology Commercialization Fund to accelerate the development of promising biomedical technologies emerging from Stony Brook University.

21 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

International team identifies key protein in development of drug-resistant leukemia

Now an international team led by researchers at the University of California, San Francisco and joined by scientists of the Freiburg excellence cluster BIOSS - Centre for Biological Signalling Studies, has identified a protein called BCL6 which plays a key role in the development of drug-resistance in leukemia.

20 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

Scientists identify key protein behind drug-resistant leukemia

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment.

19 May 2011

Vitamin D plays a key role in protection against childhood asthma

Vitamin D, which is primarily absorbed from the sun, plays a role in protection against childhood asthma. Now, a new study led by Valencian researchers has shown that children who live in colder, wetter cities are at greater risk of suffering from this respiratory problem, since there are fewer hours of sunlight in such places.

19 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi's National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Nano Bridging Molecules SA receives CE marking certification for SurfLink dental product

Nano Bridging Molecules SA, A Swiss med-tech company announced that it has received CE Mark (Conformité Européenne) approval to begin marketing its SurfLink® Dental product. With its bio mimicking properties, SurfLink® Dental has been shown to allow for natural and permanent integration of dental implants for the first time. Bone seems to perceive the SurfLink® Dental product as ‘body-like’ and integrates the implant with a natural healing process, resulting in a quicker healing and a more stable integration, than without this product.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

A new partnership to search for cancer-fighting drugs combines compound-identification and screening expertise at the University of Mississippi’s National Center for Natural Products Research with the drug development and clinical-trials capabilities at the University of Mississippi Medical Center Cancer Institute.

18 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Pfizer Inc. announced today that its New Drug Application for crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration and has been filed with the Japanese Ministry of Health, Labour and Welfare.

17 May 2011

Study reveals crucial role of histone deacetylases in type 2 diabetes

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

16 May 2011

Scientists discover new class of compounds that selectively block 'serine hydrolases'

Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery.

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Compound News and Research

H. pylori infection could play a role in Parkinson's disease development

New insights into bone diseases

Stony Brook University CFB establishes Biotechnology Commercialization Fund

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

International team identifies key protein in development of drug-resistant leukemia

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Scientists identify key protein behind drug-resistant leukemia

Vitamin D plays a key role in protection against childhood asthma

Aeterna Zentaris first quarter revenues increase to $7.4 million

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

NCNPR and Cancer Institute in Jackson partner for anti-cancer drug research

Nano Bridging Molecules SA receives CE marking certification for SurfLink dental product

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anti-cancer drug discovery partnership formed between UMMC Cancer Institute and Natural Products Center

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Study reveals crucial role of histone deacetylases in type 2 diabetes

Scientists discover new class of compounds that selectively block 'serine hydrolases'

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News